Selected IIR references (for abstracts, see Lists of IIR Publications):
Bendtzen K. Makrofaghormonerne interleukin 1 (IL-1) og tumornekrotiserende faktor (TNF). Ugeskr Laeger 1987;149:2191-6.
Mandrup-Poulsen et al. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic b-cell cytotoxicity. J Immunol 1987;139:4077-82.
Bendtzen et al. Pathogenic role of interleukin 1 and tumor necrosis factor in autoimmune endocrine diseases. Clin Immunol Newslett 1988;9:72-4.
Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988;19:183-92.
Bendtzen et al. Association between HLA-DR2 and production of tumour necrosis factor a and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol 1988;28:599-606.
Fomsgaard et al. Detection of tumour necrosis factor from lipopolysaccharide-stimulated human mononuclear cells by enzyme-linked immunosorbent assay and cytotoxicity bioassay. Scand J Immunol 1988;27:143-7.
Kharazmi et al. Modulation of human neutrophil and monocyte chemotaxis and superoxide responses by recombinant TNF-a and GM-CSF. Immunobiology 1988;177:363-70.
Oxholm et al. Immunohistological detection of interleukin 1-like molecules and tumour necrosis factor in human epidermis before and after UVB-irradiation in vivo. Br J Dermatol 1988;118:369-76.
Bendtzen K. Immune hormones (cytokines): pathogenic role in autoimmune rheumatic diseases and endocrine diseases. Autoimmunity 1989;2:177-89.
Bendtzen et al. Native inhibitors (autoantibodies) of IL-1a and TNF. Immunol Today 1989;10:222.
Fugger et al. Possible correlation of TNFa-production with RFLP in humans. Eur J Haematol 1989;43:255-6.
Bouchelouche et al. Recombinant human tumour necrosis factor increases cytosolic free calcium in murine fibroblasts and stimulates inositol phosphate formation in L-M and arachidonic acid release in 3T3 cells. Cell Signal 1990;2:479-87.
Bendtzen K. Why is too little TNF bad? Cytokine 1991;3:636-7.
Bendtzen K. Clinical significance of cytokines. Natural and therapeutic regulation. Semin Clin Immunol 1991;3:5-13.
Møller et al. Bioactive and inactive forms of tumor necrosis factor-a in spinal fluid from patients with meningitis. J Infect Dis 1991;163:886-9.
Oxholm et al. Interleukin-6 and tumour necrosis factor a are expressed by keratinocytes but not by Langerhans cells. APMIS 1991;99:58-64.
Oxholm et al. Cytokine expression in labial salivary glands from patients with primary Sjögren's syndrome. Autoimmunity 1992;12:185-91.
Kjeldsen et al. Marginal periodontitis and cytokines. A review of the literature. J Periodontol 1993;64:1013-22.
Kronborg et al. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Ped Pulmonol 1993;15:292-7.
Rieneck et al. In vitro immunomodulatory effects of pentoxifylline. Immunology Letters 1993;37:131-8.
Bendtzen K. Cytokines and natural regulators of cytokines. Immunol Lett 1994;43:111-23.
Brynskov et al. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel diseases (Crohn's disease and ulcerative colitis). A review. Dig Dis 1994;12:290-304.
Hansen et al. Tumor necrosis factor-a increases myocardial microvascular transport in vivo. Am J Physiol Heart Circ Physiol 1994;266:H60-H7.
Laham et al. Tumour necrosis factor a during human pregnancy and labour: maternal plasma and amniotic fluid concentrations and release from intrauterine tissues. Eur J Endocrinol 1994;131:607-14.
Rasmussen et al. Influence of tumour necrosis factor-a, tumour necrosis factor-b and interferon-g, separately and added together with interleukin-1b, on the function of cultured human thyroid cells. J Endocrinol 1994;143:359-65.
Bendtzen et al. Behandling af reumatoid artrit med anti-TNFa antistof. Ugeskr Laeger 1995;157:1689-90.
Sternesjö et al. Effects of prolonged exposure in vitro to interferon-g and tumour necrosis factor-a on nitric oxide and insulin production of rat pancreatic islets. Autoimmunity 1995;20:185-90.
Kjeldsen et al. Bacterial-stimulated cytokine production of peripheral mononuclear cells from patients of various periodontitis categories. J Periodontol 1995;66:139-44.Papaccio et al. An imidazoline compound completely counteracts interleukin-1b toxic effects to rat pancreatic islet b cells. Mol Med 2002;8:536-45.
Bendtzen et al. Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor a and interferon-g, and has potential in the treatment of arthritis. Clin Exp Immunol 2003;134:151-8.
Bendtzen K. Problemer ved klinisk brug af rekombinante proteiner (Editorial). Ugeskr Laeger 2003;48:4625.
Bendtzen K. Immunogenicitet af biologiske lægemidler. Erfaringer med betainterferon, EPO og anti-TNF (Immunogenicity of biopharmaceuticals. Experience with interferon-beta, EPO and anti-TNF)(Review). Ugeskr Laeger 2003;48:4629-32.
Nersting et al. Maturation of human dendritic cells by monocyte-conditioned medium is dependent on trace amounts of lipopolysaccharide inducing tumour necrosis factor. Immunol Lett 2003;89:59-65.
Hansen et al. Spironolactone inhibits production of inflammatory cytokines by human mononuclear cells. A potential mechanism for its effect in heart failure. Immunol Lett 2004;91:87-91.
Roeske-Nielsen et al. Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. Immunol Lett 2004;91:205-11.
Gudbrandsdottir et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:118-24.
Bendtzen K. Natural and therapy-induced antibodies to cytokines. Drug Discovery Today 2004;9:259.
